go back

Ranibizumab (Susvimo) Sustained-Release Implant

Delaware rates for HCPCS C9093

Injection, ranibizumab, via sustained release intravitreal implant (Susvimo), 0.1 mg

Rates data updated July 2026.

Insurance Carrier